Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15259975 | 0.91 | MTOR (0.51) | MTORPIK3CD | |
| SCHEMBL15260141 | 0.87 | MTOR (0.38) | MTORABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975300 | 0.85 | MTOR (0.37) | MTORABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17269099 | 0.85 | MTOR (0.47) | MTORABL1PIK3CD | |
| SCHEMBL16975328 | 0.84 | MTOR (0.37) | MTORABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15260270 | 0.82 | NPC1 (0.43) | ABL1NPC1RAB9ASMN1; SMN2PIK3CD | |
| SCHEMBL15260010 | 0.81 | ABL1 (0.48) | ABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17269093 | 0.80 | NPC1 (0.38) | MTORABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL15260078 | 0.80 | AURKA (0.37) | MTORABL1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL16975227 | 0.79 | MTOR (0.36) | MTORABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | SPERO GYRASE INC (US) | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260178-A1 | ANTIBACTERIAL COMPOUNDS | STS, PGLS, PEPD | MTOR 240/4885ABL1 1389/4885NPC1 1870/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.